Price movement over the last 24 hours
ARK Genomic Revolution ETF vs YieldMax TSLA Option Income Strategy ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while YieldMax TSLA Option Income Strategy ETF trades at $27.24. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | TSLY | |
|---|---|---|
Sector | Sector/Thematic | Income / Options Overlay |
52-Week High | $43.57 | $48.25 |
52-Week Low | $23.09 | $26.16 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
TSLY trades at $27.42, down slightly by 0.04% today, with a bearish technical signal from moving averages and key indicators like ADX. The ETF generates high income through weekly distributions, with recent payouts ranging from $0.28 to $0.52 per share. Support levels are at $26 and $27, while resistance lies near $28 and $29. Recent news highlights consistent dividend announcements from YieldMax, reinforcing its income-focused strategy.
The outlook for TSLY hinges on its ability to sustain high distributions amid market volatility. While the ETF offers attractive yield potential, risks include capped upside from covered call strategies and sensitivity to Tesla's stock performance. Investors should weigh income benefits against volatility and capital erosion risks in a bearish technical environment.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →